Pfizer (PFE) Ticks Higher on Expanded Lyrica Indication
Tweet
Share
E-mailGet Alerts PFE Hot Sheet
Price: $25.03 +0.08%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 6.9%
Revenue Growth %: -1.9%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 6.9%
Revenue Growth %: -1.9%
Join SI Premium – FREE
Pfizer (NYSE: PFE) shares are up early following news its Lyrica caps were approved by the FDA to manage neuropathic pain associated with spinal cord injury.
The stock is up 0.6 percent in early trade.
The stock is up 0.6 percent in early trade.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pfizer Q2 earnings preview: Analysts eye pipeline updates, portfolio resilience
- FDA grants Lilly's olomorasib breakthrough therapy status for pancreatic cancer
- Pfizer's Litfulo meets Phase 3 goals in vitiligo skin condition
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
